Pharmaceutical & Health Packaging: Cost & MOQ Guide

Overview #

Pricing a medicine carton or folding box for a pharmaceutical or health supplement brand is not as straightforward as quoting a standard retail carton — regulatory material requirements, print accuracy tolerances, and serialisation features all add cost layers that don’t exist in general consumer packaging. This guide is written for brand owners and procurement managers who are budgeting a new pharmaceutical folding carton run or benchmarking an existing supplier’s pricing. We cover the five main cost drivers in medicine carton production, how batch size affects unit economics, and where we can help you optimise spend without touching the specifications that protect your product and your compliance status. One insight upfront: the single biggest cost lever most brands overlook is not print complexity — it’s carton blank size, which directly drives board yield and therefore material cost per thousand units.

---

Cost Drivers in Medicine Carton Production #

Medicine cartons are produced from SBS (Solid Bleached Sulphate) or FBB (Folding Box Board) in the 230–350 gsm range. For OTC pharmaceutical and health supplement applications, we typically specify 300–350 gsm SBS for primary cartons requiring high stiffness and a clean white printing surface. FBB at 270–300 gsm is used where cost pressure is higher and the product is not moisture-sensitive. Board cost accounts for 35–50% of total unit cost on a standard medicine carton run, so blank size optimisation — nesting efficiency on the press sheet — is the first conversation we have with every new brand partner.

The five primary cost drivers, ranked by typical impact on unit price:

Print registration on pharmaceutical cartons must be held to ±0.2 mm on our sheet-fed offset lines — this is non-negotiable when Braille dots, barcodes, or serialisation codes are present. Tighter tolerances mean slower press speeds and higher makeready waste, both of which are reflected in the unit price at lower quantities.

Regulatory references that directly affect our material and process specifications for this category: EU Falsified Medicines Directive (2011/62/EU) for serialisation requirements on prescription cartons exported to Europe; ISO 11607 for sterile barrier packaging where the carton forms part of a secondary sterile system; and GB/T 6543 (China national standard for transport packaging) which governs corrugated outer carton performance for pharmaceutical distribution.

---

---

MOQ, Batch Size Economics, and the Break-Even Curve #

Our standard MOQ for pharmaceutical folding cartons is 5,000 units per SKU. Below that threshold, setup costs — die-cutting tooling (typically RMB 800–1,500 per unique carton blank), plate-making for offset (RMB 150–300 per colour per plate set), and QC sampling time — are spread across too few units to be commercially viable for either party.

Here is how unit cost typically scales with quantity on a standard 4-colour 300 gsm SBS medicine carton (90mm × 55mm × 20mm, matte lamination, no serialisation):

• 5,000 units: USD 0.38–0.48 per unit (setup costs dominate)
• 10,000 units: USD 0.22–0.30 per unit
• 25,000 units: USD 0.14–0.19 per unit
• 50,000 units: USD 0.10–0.14 per unit
• 100,000+ units: USD 0.07–0.10 per unit

The steepest cost drop occurs between 5,000 and 25,000 units — this is where amortising tooling and makeready across more units has the greatest effect. Beyond 50,000 units, the marginal savings per additional thousand units flatten significantly, and the main lever shifts to material purchasing volume.

For brands running multiple SKUs (e.g. a supplement line with 6 flavour variants sharing the same carton structure), we recommend a gang-run strategy: one die-cut tool shared across all variants, with colour changes handled by plate swaps. This can reduce per-SKU tooling cost by 60–70% and is standard practice on our folding carton lines for health and nutraceutical clients.

---

Where to Optimise Cost Without Compromising Compliance #

The most effective cost optimisations we guide brand partners through are structural and material — not print quality reductions, which tend to damage brand perception and can create compliance risk if text legibility is affected.

Blank size rationalisation: A 5mm reduction in carton height on a standard supplement carton can improve sheet yield by 8–12%, directly reducing board cost. We model this in our CAD layout tool before quoting and always present the yield comparison.

Board grade substitution: For health supplement cartons (non-prescription, no moisture-sensitive product), switching from 350 gsm SBS to 300 gsm FBB typically saves 10–18% on board cost with no functional performance loss, provided the carton is not a primary container for a regulated pharmaceutical product. We always confirm the regulatory classification before recommending a downgrade.

Finishing consolidation: Combining matte lamination with inline cold foil (rather than a separate hot foil pass) reduces finishing passes from two to one, cutting production time by approximately 15% and reducing the risk of registration shift between passes.

AQL sampling: Our standard incoming board inspection runs at AQL 2.5 (ISO 2859-1), and finished carton inspection at AQL 1.0 for critical defects (print legibility, Braille accuracy, barcode readability) and AQL 2.5 for major defects (colour delta, crease quality). Brands that require tighter AQL levels — some pharmaceutical clients specify AQL 0.65 for prescription carton lines — should budget for extended inspection time, which adds approximately USD 0.005–0.012 per unit at volumes under 50,000.

---

Specification Notes for Brand Partners #

When you brief us on a pharmaceutical or health supplement folding carton, the most useful information you can provide upfront is: finished carton dimensions (L × W × H in mm), product weight and fragility (this determines whether we need an insert tray or auto-bottom construction), regulatory classification (OTC, prescription, or supplement — this determines board grade and serialisation requirements), and target market (EU, US, AU, or domestic China, as each has different language, font size, and barcode format requirements).

The most common brief mistake we see is brands specifying a carton size based on an existing supplier’s sample without checking whether that size is yield-optimised for our press sheet dimensions. We run 720mm × 1,020mm and 1,050mm × 740mm sheet formats — a carton blank sized for a different press format can waste 15–20% of board area and inflate your unit cost unnecessarily. We catch this in the first CAD review and propose an adjusted size if the dimensional tolerance allows.

Our typical process: digital proof in 3–5 working days, physical pre-production sample in 10–14 working days, production lead time 18–25 working days after sample approval for standard folding carton runs. Serialisation or Braille embossing adds 3–5 working days to the production schedule.

---

Frequently Asked Questions #

Q1: What is the minimum board weight you recommend for a pharmaceutical folding carton, and why does it matter for cost?
A: For primary pharmaceutical cartons, we specify a minimum of 300 gsm SBS — below this, panel stiffness is insufficient for automated filling line handling and the carton is prone to crushing under the 3–5 kg compression loads typical in secondary packaging. Using 270 gsm FBB instead of 300 gsm SBS saves approximately 10–18% on board cost but is only appropriate for health supplement or nutraceutical applications where the regulatory classification permits it.

Q2: What is your MOQ for medicine cartons, and how does it affect unit pricing?
A: Our standard MOQ is 5,000 units per SKU. At this quantity, unit cost on a standard 4-colour 300 gsm SBS carton runs USD 0.38–0.48 — roughly 4–5× the unit cost at 100,000 units. If you have multiple SKUs sharing the same carton structure, we recommend a gang-run approach that can reduce per-SKU tooling cost by 60–70% and bring the effective MOQ economics closer to a 25,000-unit run.

Q3: Do your pharmaceutical cartons comply with EU serialisation requirements under the Falsified Medicines Directive?
A: Yes. For prescription pharmaceutical cartons destined for EU markets, we produce cartons compatible with the EU Falsified Medicines Directive (2011/62/EU) serialisation requirements, including 2D Data Matrix barcode printing and tamper-evident feature integration. Inline inkjet serialisation adds approximately USD 0.008–0.015 per unit depending on volume, and we validate barcode readability to ISO/IEC 15415 grade standards before shipment.

Q4: Can you combine Braille embossing with spot UV finishing on the same carton?
A: Yes, we run Braille embossing and spot UV as separate passes — Braille is applied post-lamination using a dedicated embossing die, and spot UV is applied before lamination in our standard sequence. The key constraint is that Braille dot height must meet EN 15823 (minimum 0.2mm dot height, 0.6mm dot diameter) — we verify this with a contact profilometer on the first production sample. Combining both finishes adds approximately 18–30% to the finishing cost versus matte lamination alone.

Q5: What is the most common quality issue on pharmaceutical carton runs and how do you prevent it?
A: The most frequent issue we see is barcode print contrast failure — specifically, insufficient PCS (Print Contrast Signal) on barcodes printed over a coloured background panel. This typically occurs when the background ink density exceeds 40% and the barcode is printed in the same pass without a white underprint. Our standard prevention is to specify a minimum 3mm white clear zone around all barcodes and run inline barcode verification at 100% on pharmaceutical carton lines. Any carton with a barcode PCS below 0.75 (per ISO/IEC 15416) is automatically rejected before packing.

---

Planning a pharmaceutical or health supplement packaging project? Contact our team to request a complimentary specification review and sample quote.

---